Please enlighten you, not "us". Sure. This is all my opinion of course. We had positive A2 results, which proves it can be taken for long periods. We have increasing QoQ revenue. These two factors will remain.
The share price and lack of management communication is causing that bitter taste in majority of retail shareholders. It also leads them to capitulate and bad talk the company. This causes the share price to fall more as it scares new investors and less retail capital comes in.
But if you ignore this noise, focus on the positive data, and increasing revenue. You know nothing has changed. From $0 revenue from sales in 2019, to $42 million in 2021, to over $100 million projected by end of 2022. Yoy growth will continue. Otsuka also submitted to EMA in June or July of 2021, this approval will probably come in August or September this year, further increasing revenue from the European market. 2023 revenue will be much higher. AUPH is at clinical stage prices with an FDA approved drug. The negative sentiment allows me to accumulate more shares at a lower price. I know another spike in share price is coming. It may take a week, month, year, or years, But i know its coming. All just my opinion and of course I could be wrong.
Good luck Sir
News 
Market Data 
Discover 
AI
